Sara Mariotto, MD, PhD - Beyond Myasthenia Gravis: What Are We Learning About FcRn Inhibitors in Other Rare Neuroimmunological Disorders?

Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

Jörn M. Schattenberg, MD - Cases in Contemporary MASH Management: Expert Insights on the Practical Integration of Disease-Specific Pharmacotherapy

Naim Alkhouri, MD, FAASLD, DABOM - Don’t Wait, and Look Beyond Weight: The Growing Case for Urgent and Comprehensive Management of MASH

Colin Russell, PhD / John Watkins, MBBCh, BSc - A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact

Erwan Donal, MD, PhD / Nina Ajmone Marsan, MD, PhD - At the Cutting Edge of ATTR-CM: How Can We Leverage Advances in Multimodality Cardiac Imaging and Artificial Intelligence to Modernise Diagnosis and Monitoring?

Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: Breaking Down the Data Driving Therapeutic Developments in IgA Nephropathy

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: A Fresh Look at the Data Driving Targeted Therapeutic Developments in IgA Nephropathy

David Alain Wohl, MD - Inpatient Management of SARS-CoV-2 Infection: Applying Learnings From Real World Evidence to Real World Practice